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Methods: A comprehensive literature review was performed to identify all studies that dis-
cussed the physiologic, clinical and societal consequences of obstructive sleep apnea syn-
drome as well as the costs associated with these consequences. There were 106 studies that
formed the basis of this analysis.
Conclusions: Undiagnosed and untreated obstructive sleep apnea syndrome can lead to
abnormal physiology that can have serious implications including increased cardiovascular dis-
ease, stroke, metabolic disease, excessive daytime sleepiness, work-place errors, traffic acci-
dents and death. These consequences result in significant economic burden. Both, the health
and societal consequences and their costs can be decreased with identification and treatment
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quences, is limited by lack of diagnosis, poor patient acceptance, lack of access to effective
therapies, and lack of a variety of effective therapies. Newer modes of therapy that are effec-
tive, cost efficient and more accepted by patients need to be developed.
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Sleep disorders and specifically obstructive sleep apnea
syndrome (OSAS) have been increasingly recognized as sig-
nificant health problems in the last two decades.1 OSAS is a
condition in which repetitive episodes of airway occlusion
occur during sleep, resulting in apneas or hypopneas and
related arousals. These events lead to intermittent hypox-
emia, increased sympathetic tone, cytokine production,
metabolic abnormalities, and abnormal sleep structure. This
abnormal physiology results in increased health risks, most
notably those related to the cardiovascular and cerebro-
vascular systems. It also leads to neurocognitive abnormal-
ities, which have significant societal consequences.
The term obstructive sleep apnea (OSA) generally refers
to objective laboratory findings. The term obstructive sleep
apnea syndrome (OSAS) refers to the combination of the
laboratory finding of OSA plus clinical consequences related
to the events such as excessive daytime sleepiness. A
diagnosis of OSAS is generally derived from one of three
diagnostic modalities: full-night polysomnography (PSG),
split-night PSG and unattended portable home monitoring.
Unattended portable home sleep tests are being used with
growing frequency, although full-night PSGs are still
considered the gold standard for evaluation of OSAS. The
number of apneas and hypopneas per hour of sleep is
termed the apneaehypopnea index (AHI). This paper is
primarily focused on moderate OSAS, defined as AHI 15
and severe OSAS defined as AHI 30.2
Research has established links between OSAS and several
important co-morbidities. Recent studies have shown a
clear association of OSAS with the development of hyper-
tension,3e5 type II diabetes,6,7 stroke,8e11 congestive heart
failure,12 coronary artery disease,8,13e16 cardiac arrhyth-
mias17 and even early mortality.18e20 OSAS remains signifi-
cantly under recognized, and it is estimated that only 40%
of those with OSAS have been diagnosed.2 In addition, the
obesity epidemic in the United States potentiates explosive
growth of this disease entity.
The consequences of undiagnosed and untreated OSAS
are medically serious and economically costly.21 Continuous
positive airway pressure (CPAP) is considered the gold
standard of treatment for OSAS. When adherence is
optimal, CPAP improves sleep quality, reduces the risk of
OSAS-related co-morbidities and improves patient quality
of life.14,22e25 However, in spite of many technological
advances of the CPAP apparatus and the patientedevice
interface, adherence remains a significant problem.26,27
Surgical treatment options for OSAS, other than tra-
cheostomy, can be effective for some properly selectedpatients, but overall, results are equivocal. In addition to
mixed results, OSAS surgeries often involve high morbidity,
long recovery times, and low patient acceptance.28,29
Recently, there has been examination of other treatments
(e.g. mandibular advancement devices (MAD), and hypo-
glossal nerve stimulation in reducing risk of co-
morbidities).30e32
In this review, we discuss the physiologic consequences
and the resultant economic burden related to the health
problems of OSAS.
Methods
A comprehensive search was performed in the PubMed
database with no date restrictions. The search term used
included “OSA,” “OSAS,” or “sleep apnea” to search for
OSAS. To search for consequences and costs, the following
search terms were used: “consequences,” “trans-
portation,” “crashes,” “accidents,” “job,” “depression,”
“heart failure,” “stroke,” “arrhythmia,” “diabetes,”
“cost,” “heart attack,” and “hospitalization.” Articles were
chosen for recency and relevance to the specific topics
discussed below.
Results
With the above criteria, we found the following number of
articles for each section that informed the basis of this
review: Medical consequences, 4025 articles; Trans-
portation consequences, 81 articles; Workplace conse-
quences 66 articles; Economic consequences 466 articles
and treatment options, 5758 articles. The authors chose
data from 106 exemplary articles as the basis of this review.
Prevalence
The Wisconsin Sleep Cohort Study is a landmark study that
evaluated the prevalence of sleep apnea in state em-
ployees. It demonstrated that 24% of men and 9% of women
had mild to severe OSAS (AHI  5).2 This translates to about
29.5 million people over the age of 30 in the United States.
It also showed that 4% of women and 9% of men have
moderate to severe OSAS (AHI  15), which translates to
about 13 million people over the age of 30 in the U.S.2 In
addition, the prevalence is much higher in certain patient
populations. For example, 55% of patients with docu-
mented coronary artery disease and 37% of patients with
diabetes (type I and II) have moderate to severe OSAS.33,34
Cost of untreated obstructive sleep apnea 19Medical consequences of untreated OSAS
The consequences of undiagnosed and untreated OSAS are
numerous and serious (see Fig. 1 and Table 13550). During
sleep, OSAS patients experience recurrent airway obstruc-
tion (in the form of apneas and hypopneas). An increase in
heart rate and a surge in blood pressure are seen during
these events and, as a result, the events cause repeated
strain on the heart and circulatory system throughout the
night.51,52 The arousals, which terminate the airway oc-
clusion, are accompanied by a sympathetic nervous system
response.53 Evidence suggests that this sympathetic acti-
vation from nocturnal events persists during the daytime as
well.54,55 Consequently, OSAS patients tend to have higher
heart rates, less heart rate variability, higher blood pres-
sure and increased arterial stiffness compared to healthy
controls.51,56 It is not surprising that multiple studies have
found OSAS patients to be at increased risk for cardiovas-
cular morbidities and hypertension.3e5,8,10e12,14,15 These
patients are also at an increased risk for early all-cause
mortality, and, as one might expect, cardiovascular mor-
tality risk is high (adjusted hazard ratio Z 5.2 (95% CI 1.4,
19.2)).18e20 OSAS has been associated with metabolic dis-
orders,57e60 and elevated risk for cancer and mortality
among OSAS patients, particularly for those with severe
OSAS (AHI  30).61,62 Perioperative complications including
need for prolonged intubation, need for re-intubation,
pneumonias, aspiration, arrhythmias and cardiac arrest
are increased in those with untreated sleep apnea.63e65
Recent evidence suggests that when sleep apnea is diag-
nosed prior to surgery, the risk of cardiac and neurovascular
events is decreased by about 50%, and it is comparable to
those individuals that do not have sleep apnea.50
OSAS patients experience daytime sleepiness, decreased
cognitive function and are at an increased risk for co-
morbidities and accidents. Not surprisingly, studies have
consistently found OSAS patients report lower quality of life
than non-OSAS patients (see Table 2).66e68 The bed part-
ners of OSAS patients also assess the quality of life for their1.1
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Fig. 1 Increased risk in obstrupartner to be lower than individuals without OSAS.69 The
prevalence of depression in this population has been sited
to be as high as 50%.70,71 When the patient’s OSAS is
treated, quality of life and symptoms of depression
improve.22,70 The challenge, as mentioned above, is long-
term adherence with CPAP. If CPAP is not used as
directed, lowered quality of life and possibly depression
will persist.
Transportation consequences of untreated
OSAS
Sleep-related respiratory events interrupt physiological
sleep structure and inhibit sleep-based functional recovery.
This leads to excessive daytime sleepiness, impaired vigi-
lance, decreased ability to adequately perform daily tasks
and ultimately, accidents. The increased risk of motor
vehicle crashes among patients suffering from OSAS has
been well documented (see Table 3).72e76 Although specific
risk factors for automobile crashes among those with OSAS
have yet to be determined, improvement in vigilance and
motor vehicle crash rates with effective CPAP therapy has
been documented.73,77,78 The costs (in lives and dollars)
specifically related to OSAS-related motor vehicle crashes
are significant. In 2004, Sassani and colleagues estimated
that 810,000 motor vehicle crashes a year are attributable
to OSAS, resulting in 1400 fatalities and costing roughly
$15.9 billion.79 Their research also concluded that treating
the same OSAS sufferers with CPAP, assuming 70% adher-
ence, would prevent roughly 500,000 collisions, save 1000
lives and reduce cost by $11.1 billion. The cost of CPAP was
factored into the dollars saved.79
Workplace consequences of untreated OSAS
Consistent with the findings on motor vehicle crashes, OSAS
sufferers are also at an increased risk for workplace acci-
dents. Lindberg and colleagues found that survey5 10
Hazard Ratio
Odds Ratio
Relative Risk
ctive sleep apnea syndrome.
Table 1 Untreated OSAS puts patients at increased risk for the following health conditions.
Condition Quantified risk Quantified costs Reference
Hypertension Sleep apnea is an independent risk
factor for hypertension. 89% of
patients with resistant hypertension
have moderate sleep apnea. About
50% of essential hypertension
patients have sleep apnea; about 50%
of apnea patients have hypertension.
In 2010 high blood pressure cost the
US $93.5 billion in health care
services (Centers for Disease
Control). In 2008 the cost of treating
hypertension in the US was $50.6
billion (American Heart Association
(AHA)). Patients with OSAS are 2e3
times more likely to be taking
antihypertensive medications than
controls (more prescriptions, more
doses, greater cost).
Pepperd 20003
Nieto 20004
Otake 200244
Young 20092
Lurie 201135
Pedrosa 201136
Roger 201284
Phillips 20135
Lloberes 201498
Schein 201423
Heart failure Male patients with OSAS are 6 times
or more likely to be treated for
congestive heart failure compared to
controls. OSAS patients have reduced
left ventricular ejection fraction.
It has been estimated by the AHA that
the cost of treating heart failure in
the USA in 2015 will be $44.6 billion.
Shahar 200112
Smith 200271
Roger 201284
Sun 201337
Arrhythmias Atrial fibrillation is very common in
sleep apnea. Untreated sleep apnea
independently predicts atrial
fibrillation recurrence in patients
undergoing ablation therapy. Patients
with severe OSAS are less likely to
respond to antiarrhythmic drug
therapy. OSAS patients who had a
stroke had higher rates of atrial
fibrillation.
The annual direct cost of treating a
single patient with atrial fibrillation is
$8705. The annual cost to the USA is
$26 billion.
Gami 200838
Albuquerque 201239
Bitter 201240
Monahan 201242
Mansukhani 201241
Roger 201284
Goyal 201499
Vizzardi 201417
Coronary artery
disease
Men with sleep apnea are more likely
to have coronary heart disease, and
are more likely to have fatal and
nonfatal cardiovascular events if
untreated. Women with sleep apnea
also have increased risk of coronary
heart disease, and their risk is
attenuated by use of CPAP.
The cost of coronary heart disease in
the US is about $190 billion per year.
The average cost for treating acute
myocardial infarction in 2006 was
about $14,000 per patient.
Selim 201015
Marin 201214
Roger 201284
Loo 201413
Campos-Rodriguez 20148
Stroke There is a strong association between
sleep apnea and the subsequent
development of ischemic stroke,
which can be attenuated with CPAP
use.
The cost of treating stroke in the US
in 2008 was $34.3 billion (AHA). The
lifetime cost of treating a single
patient with stroke is likely between
$100,000 and $300,000.
Taylor 199685
Yaggi 200511
Redline 201010
Roger 201284
Cho 201343
Campos-Rodriguez 20148
Metabolic syndrome Sleep apnea is associated with the
metabolic syndrome in women and
men.
The age-adjusted prevalence for
metabolic syndrome is 35.1% for men
and 32.6% for women. Each
component of the syndrome is
associated with increased costs for
hypertension ($550), obesity ($366),
low high-density lipoprotein ($363),
and high triglycerides ($317)
(P < 0.001 for all).
Nichols 201159
Hall 201258
Roger 201284
Schmitt 201360
Lin 201457
Type II diabetes In adults without known diabetes,
increasing OSAS severity is
independently associated with
impaired glucose metabolism, higher
HbA1c values, increasing them to
higher risks of diabetes. Sleep apnea
is associated with impairments in
insulin sensitivity, glucose
effectiveness, and pancreatic
beta-cell function.
In 2007, the direct ($116 billion) and
indirect ($58 billion) cost attributable
to diabetes was $174 billion.
Reichmuth 20056
Punjabi 20097
CDC 201145
Priou 201247
Guest 2014100
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Table 1 (continued )
Condition Quantified risk Quantified costs Reference
Depression Depression is more than two times
more common in females with sleep
apnea than the general population.
Depressive symptoms may improve
with apnea treatment.
The cost of depression was $ 83.1
billion dollars in 2000: $ 26.1 billion
(31%) were direct medical costs, $5.4
billion (7%) were suicide-related
mortality costs, and $51.5 billion
(62%) were workplace costs.
Smith 200271
Greenberg 200346
El-Sherbini 201170
Gagnadoux 2014101
Adverse perioperative
event
Untreated sleep apnea patients are
much more likely to develop serious
perioperative events including
cardiac arrest and respiratory failure
that require ICU stays.
Mean intensive care unit cost and
length of stay were $31,574 and 14.4
days for patients requiring
mechanical ventilation and $12,931
and 8.5 days for those not requiring
mechanical ventilation.
Dasta 200549
Vasu 201248
Gaddam 2013102
Memtsoudis 201464
Stundner 201463
Mutter 201450
Cancer Cancer rate is increased particularly
in patients with hypoxemia and with
sleep apnea. Cancer-related
mortality increases with hypoxemia
and severity of sleep apnea in
younger patients.
Unknown Rich 201119
Nieto 201261
Martinez-Garcia 2014103
Chen 2014104
Marshall 2014105
Death Death rate is increased, particularly
in patients less than 50 years of age.
Not applicable Young 200818
Rich 201119
Marshall 2014105
Cost of untreated obstructive sleep apnea 21respondents reporting both snoring and excessive daytime
sleepiness over a ten-year period were at a greater risk for
workplace accidents, odds ratio of 3.1 (1.5e6.4).80 A limi-
tation of the Lindberg study is that they only categorized
subjects based on snoring and daytime sleepiness: PSG was
not performed to confirm a diagnosis of OSAS. In addition,
their study was a retrospective study that relied on patient
self-reports of errors made. However, it seems reasonable
to assume that many of those reporting snoring and
excessive daytime sleepiness were reporting symptoms that
resulted from OSAS. The negative impact on workplace
disability resulting from OSAS is also important to consider.
Omachi and colleagues found that individuals suffering
from OSAS and reporting excessive daytime sleepiness
experience a significantly greater risk of workplace
disability than those with no OSAS and no daytime sleepi-
ness, odds ratio of 13.7 (95% confidence interval [CI],
3.9e48). These same individuals also experience anTable 2 Untreated OSAS significantly diminishes patient quality
Condition Quantified risk Qua
Home Patients with sleep apnea have an
impaired quality of life that affects
both the patient and family members.
Quality of life improves with
treatment.
Not
Workplace Patients with OSAS are about ten
times more likely to have workplace
disability. This has the potential of
increasing costs to employers in the
realms of reduced productivity,
healthcare costs and liability in the
event of accidents.
The
cal
tha
red
takincreased risk of long-term duty modification as a result of
their OSAS.81 A more recent study by Guglielmi and group
evaluated the relationship between severity of OSAS by
polysomnographic measures and sleepiness and job satis-
faction in individuals with and without OSAS.82 They found
that subjective sleepiness in OSAS patient did influence job
satisfaction and burnout regardless of OSAS severity by
polysomnographic parameters. The same group reported in
another paper that absenteeism and productivity were
worse among OSAS patients.83Economic consequences of untreated OSAS
The increased risk of health complications, work-place er-
rors and traffic accidents in OSAS patients conveys signifi-
cant costs in terms of healthcare dollars and the overall
economy. Case in point is the cost of care for two of theof life.
ntified costs Reference
applicable Finn 199866
Baldwin 200167
Breugelmans 200469
Siccoli 200822
Warkentin 2014106
cost of absenteeism is difficult to
culate but, Hoffman et al. found
t treating OSAS patients with CPAP
uced the % of Commercial Drivers
ing short-term disability by 50%
Omachi 200981
Vennelle 201068
Hoffman 201090
Table 3 Untreated OSAS puts patients and the public at increased risk for accidents.
Condition Quantified risk Quantified costs Reference
Motor Vehicle Accidents The rate of vehicle crashes (personal
and commercial) is at least double in
OSAS patients compared to controls.
These crashes often result in personal
injury. Many drivers in head-on
crashes are found to have OSAS.
Treatment reduces the accident rate.
This improvement with treatment is
most evident in the most severely
affected patients.
In 2000, conservative calculations
found that more than 800,000 drivers
were involved in OSAS-related motor-
vehicle collisions in the United States.
These collisions cost $15.9 billion and
1400 lives. In the United States,
treating all drivers suffering from
OSAS with CPAP would cost 3.18
billion dollars, save 11.1 billion
dollars in collision costs, and save 980
lives annually
Sassani 200479
Ellen 200675
Tregear 200976
Antonopoulos 201174
Karimi 201473
Work Related Accidents Workplace accidents are particularly
more common in OSAS patients when
they are in the transportation
industry.
The costs of workplace accidents are
difficult to quantitate precisely
because of the direct and indirect
costs. However, OSAS is now
considered a public health hazard
given its pervasive effects in the
workplace.
Lindberg 200180
Vennelle 201068
Leger 201272
22 M. Knauert et al.most significant consequences of untreated OSAS: stroke
and myocardial infarction. Broadly, the cost of coronary
heart disease in the United States is estimated at roughly
$190 billion per year and the average cost for treating acute
myocardial infarction in 2006 was roughly $14,000 per pa-
tient.84 The cost of treating stroke in the United States in
2008 was $34.3 billion and the lifetime cost of treating a
single patient with stroke is estimated between $100,000
and $300,000.84,85
Case-controlled studies have specifically evaluated the
cost impact of OSAS and have demonstrated that overall
healthcare utilization costs are higher for undiagnosed
OSAS patients. Three such studies include Kapur et al.,
1999, Tarasiuk et al., 2005 and Albarrak et al., 2005.86e88
After normalizing the results to a common currency (US$)
and adjusting for inflation, it is estimated that increased
healthcare spending to treat undiagnosed OSAS patients is
between $1950 and $3,899, per patient, per year. Taking an
estimated prevalence of 29.5 million people extrapolated
from the Wisconsin Sleep Cohort data, if 60% remain undi-
agnosed, an estimate of the added burden on the health-
care system is between $34 billion and $69 billion annually
(Table 4).Table 4 Untreated OSAS has a significant economic burden on
Condition Quantified risk
Economic burden
of OSAS
Patients with undiagnosed OSAS have
higher medical costs than non-OSAS
patients.
Patients with diagnosed but,
untreated OSAS, have higher medical
costs compared to patients not
receiving treatment for their OSAS.Several additional studies were reviewed that specif-
ically evaluated the effect of treating OSAS versus not
treating. It should be noted here that commercial motor
vehicle operators appear to be early adopters of a well-
organized strategy to address OSAS in their workforce
populations. Because of this, perhaps two of the most
useful studies looking at the impact of appropriately
treating OSAS originate within the commercial motor
vehicle population.
The first study was a retrospective analysis conducted by
Berger et al. in 2006.89 The authors analyzed healthcare
costs for a population of 337 commercial vehicle drivers,
before and after the initiation of CPAP treatment. They
found an overall reduction in healthcare costs of 48%, from
$906.28 per member, per month to $472.69 per member,
per month. They also found a significant reduction in the
accident rate from 93% pre-CPAP treatment to 25% post-
CPAP treatment.89 Although the authors ended their anal-
ysis here, improvements in cost and worker productivity
most certainly followed this reduction in workplace
accidents.
The second study, published by Hoffman et al. in 2010,
was a retrospective analysis of commercial motor vehiclesociety and employers.
Quantified costs Reference
Undiagnosed OSAS patients cost
$1950 to $3899 per year more than
non-OSAS patients.
Kapur 199988
Albarrak 200586
Tarasiuk 200587
Berger 200689
Hoffman 201090
OSAS patients that are treated with
CPAP cost $2700-$5200 less per year,
than OSAS patients not receiving
treatment
Berger 200689
Hoffman 201090
Fig. 3 Percent of drivers taking short term disability leave.
Cost of untreated obstructive sleep apnea 23drivers that compared diagnosed OSAS patients receiving
treatment via CPAP (n Z 156) to a control group (n Z 92)
that was not receiving treatment. They found that annual
healthcare costs decreased by 37% one year post treatment
and noted further decrease to by 41% decrease in annual
healthcare costs when comparing the second year with
treatment to pre-treatment healthcare costs (see Fig. 2).90
They also found that the percentage of drivers taking short-
term disability leave decreased by about 50% in the 2 years
following treatment compared to a year prior to treatment
(see Fig. 3).90
OSAS treatment options
According to the American Academy of Sleep Medicine,
OSAS is a chronic disease that requires long-term
multidisciplinary management. Conservative therapeutic
approaches are generally initial recommendations that
include: CPAP or mandibular advancement devices, weight
loss and measures to improve sleep hygiene. CPAP is
offered for all patients with moderate to severe disease
and to patients with mild disease and clinical evidence of
daytime sleepiness. In recent work, Kim et al. defined CPAP
treatment success as reducing AHI to <10 in patients
(n Z 151) with moderate and severe OSAS. By this defini-
tion, 92% of non-obese patients (BMI <25) and 79% of obese
patients received successful treatment with CPAP.
Furthermore, among non-obese patients, 82% of patients
with moderate OSAS and 94% of patients with severe OSAS
patients were adherent to CPAP for more than four hours
per day for more than 70% of days. In obese patients,
adherence by this definition was 94% in moderate OSAS and
76% in severe OSAS.91 In a contrasting study, Kuna et al.
showed a lower adherence to CPAP patients with moderate
to severe apnea. In their study, adherence was 52% in the
105 patients who underwent home sleep testing and 49% in
the 96 who underwent in-laboratory polysomnogram.
In the event that CPAP is not effective or is not tolerated
by the patient, there are alternate therapies, which include
surgical procedures to implement varying levels of airway
reconstruction. Uvulopalatopharyngoplasty (UPPP) involves
excision of the tonsils, posterior soft palate and uvula, and
closure of the tonsillar pillars. Success, defined as aFig. 2 Health plan costs for treated drivers.reduction in AHI by 50% and less than 20, was noted to be
much lower with UPPP than that of CPAP by Kim et al.; in 70
patients with AHI >15 who underwent UPPP and/or tongue
base radiofrequency ablation, they found that 48% of obese
and 43% of non-obese patients achieved treatment success
at one year.91 The relative failure of UPPP was echoed in a
recent meta-analysis.92 The incidence of serious nonfatal
complications and 30-day mortality after UPPP are 1.5% and
0.2%, respectively, in a large cohort of UPPP patients at
veteran hospitals.93 Maxillo-mandibular advancement
(MMA) is a skeletal surgery designed to enlarge the velo-
orohypopharyngeal airway by advancing the anterior
pharyngeal tissues attached to the maxilla, mandible, and
hyoid bone. In a meta-analysis of surgical OSAS treatments
via MMA, 234 subjects with severe OSAS and a mean AHI of
54.4 per hour had an overall reduction in AHI of 87% (95% CI
80%e92%) with a mean postoperative AHI of 7.7.92 Despite
its efficacy, acceptance of MMA has been variable due to
patient’s concerns over the invasiveness of the procedure,
and poor insurance coverage for maxillofacial related pro-
cedures. Surgical placement of a tracheostomy was one of
the earliest methods of treating obstructive sleep apnea. It
has been shown to be effective in reducing the number of
respiratory events, decreasing sleepiness and reducing
mortality.94 However, its use is limited obvious cosmetic
concerns and patient acceptance.
Mandibular advancement devices (MADs) reposition the
lower jaw and/or the tongue to increase the dimensions of
the retroglossal airway lumen. These devices are generally
recommended for patients with less severe sleep apnea and
are considered better tolerated than positive airway pres-
sure therapy. However, these devices do not achieve the
same reduction in AHI as other modalities.95 In a cross-over
study of 126 patients with moderate to severe OSAS who
were sequentially treated with CPAP followed by MAD (or
the reverse), CPAP was more efficacious than MAD in
reducing AHI (CPAP AHI, 4.5  6.6/h; MAD AHI, 11.1  12.1/
h; P < 0.01) but reported adherence was higher on MAD
(MAD, 6.50  1.30 h per night vs. CPAP, 5.20  2.00 h per
night; P < 0.00001).95 Moreover, most insurance companies
do not cover the cost of MAD, leaving the patients to bear
the cost themselves. Because the cost of these devices can
be high, especially with possibility of poor efficacy, it may
deter patients from their use.
24 M. Knauert et al.More recent studies have demonstrated the efficacy of
implantable unilateral hypoglossal nerve stimulation as
treatment for moderate and severe OSAS is a very select
group of patients.32,96,97 This modality involves the im-
plantation of a device with a stimulation electrode over the
hypoglossal nerve and a sensing electrode near the inter-
costal muscles to sense respiratory effort. The objective is
to stimulate the hypoglossal nerve to recruit tongue pro-
trusion in order to maintain airway patency during sleep
while ensuring synchrony with respiratory effort. Strollo
et al. evaluated the utility of this device in patients with an
AHI of 20e50/hour on baseline polysomnogram and a body-
mass index less than 32 kg/m2 who could not tolerate CPAP.
They showed that there was a reduction of AHI from a
baseline value of 29.3 to 9.0 events per hour. In addition,
they demonstrated an improvement in the oxygen desatu-
ration index, functional outcomes defined by responses to a
sleep questionnaire and the Epworth Sleepiness Scale.
However, the anatomic features of the patients enrolled in
this study were very specific, and therefore this treatment
may not be generalizable. Further data is also needed on
improvement in other health outcomes with the use of this
approach to treatment of OSAS.
Limitations of this review
Despite the apparent impact of OSAS, there are very few
studies that quantitatively evaluate the true cost of the
disease. Perhaps this is due to the recency of the recog-
nition of OSAS as a public health problem, or perhaps due
to the large number of detrimental and sometimes inter-
acting outcomes of untreated OSAS. As just one of many
possible examples OSAS is associated with arterial hyper-
tension, which in turn is associated with coronary artery
disease. Many of the existing studies and a summary of
their findings were discussed above. However, this review
is limited by the scarcity of studies to evaluate this
problem.
Implications for practice
The consequences of undiagnosed and untreated OSAS are
serious, and the medical and societal costs are very high.
Identification of those patients with yet undiagnosed sleep
apnea and treating them is therefore vital. The current gold
standard of treatment for OSAS is CPAP therapy, which has
been shown to improve sleep quality, reduce the risk of co-
morbidities and improve patient quality of life. However,
adherence to CPAP remains poor in many patients, and this
remains a significant problem. When a patient fails CPAP,
alternate therapies including oral devices and surgical
therapies should be considered. Surgical treatment options
for OSAS can be effective for properly selected patients,
but overall, accessibility, acceptability and clinical results
are mixed. Oral devices are effective in only a selected and
generally mildly to moderately affected patient pop-
ulations. In order to address these unmet therapy needs,
the medical community needs new treatment options to
tackle OSAS, reduce the risk of dangerous co-morbidities
and improve quality of life for people suffering from this
debilitating condition.Disclosure
This manuscript did not have financial support.
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discussed within this manuscript.References
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